Floatz logo

Catequentinib

Lung Neoplasm

The First Affiliated Hospital of Xinxiang Medical CollegeSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

51 Active assets in the Lung Neoplasm cohort.

Asset / SponsorPhaseRating
Carboplatin
Nanfang Hospital, Southern Medical University
Phase 4BB
BELAGENPUMATUCEL-L (SK-LU-1)
NovaRx Corporation
Phase 3BB
Nivolumab
Hospital Israelita Albert Einstein
Phase 2BB
Icotinib
Fuda Cancer Hospital, Guangzhou
Phase 4BB
Pralsetinib, trans-
Hoffmann-La Roche
Phase 3BB

View all 50 →

Same molecule, other indications

Catequentinib is also rated in:

AnlotinibDormant
BB
Indicative ·
71 / 100
View asset →
refractory malignant neoplasmDormant
BB
Indicative ·
70 / 100
View asset →
kidney cancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →